mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma

Prostate cancer patients with localized disease are treated with curative intent. However, the disease will recur in approximately 30% of patients with a high incidence of morbidity and mortality. Prognostic biomarkers are needed to identify patients with high risk of relapse. mTOR pathway activatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Stelloo, Suzan, Sanders, Joyce, Nevedomskaya, Ekaterina, de Jong, Jeroen, Peters, Dennis, van Leenders, Geert J.L.H., Jenster, Guido, Bergman, Andries M., Zwart, Wilbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078062/
https://www.ncbi.nlm.nih.gov/pubmed/27096957
http://dx.doi.org/10.18632/oncotarget.8767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078062/
https://www.ncbi.nlm.nih.gov/pubmed/27096957
http://dx.doi.org/10.18632/oncotarget.8767

Ejemplares similares